Previous 10 | Next 10 |
Highlights Orphazyme’s Establishment of U.S. Headquarters in Chicago and Recruitment of More Than 30 U.S. Employees Comments That Orphazyme’s Investments in the U.S. are Intended to Support Regulatory Efforts and the Prospective Commercialization of Arimocl...
CytRx (CYTR): Q3 GAAP EPS of -$0.08.Cash and cash equivalents of $12.06M.10QPress Release For further details see: CytRx reports Q3 results
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the third quarter ended Septe...
Applauds Orphazyme’s Efforts to Pursue Approval in Europe for Arimoclomol in the Treatment of Niemann-Pick Disease Type C Notes That Arimoclomol for Niemann-Pick Disease Type C is Under the FDA’s Priority Review With a Target Action Date of March 17, 2021 ...
Applauds Orphazyme for Investing in Commercial and Other Pre-Launch Activities in Preparation of Potential FDA Approval of Arimoclomol to Treat Niemann-Pick Disease Type C Arimoclomol for Niemann-Pick Disease Type C is Under the FDA’s Priority Review With a Target...
Third-Line Cohort Added to Phase 2 Pancreatic Cancer Trial for Combination Immunotherapy That Includes Aldoxorubicin, ImmunityBio’s N-803 and NantKwest’s PD-L1 t-haNK Three Trial Sites in California and South Dakota Will Initially Enroll 298 Patients Across...
Reid’s Stage IV Pancreatic Cancer is Reportedly in “Complete Remission” After Combination Immunotherapy That Included NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803 and Aldoxorubicin ImmunityBio and NantKwest Announced in May 2020 That T...
CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today congratulated Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) ( ...
FDA’s Priority Review Shortens Assessment Period to 6 Months, Resulting in a Target Action Date of March 17, 2021 Under PDUFA CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseas...
Highlights That Stockholders Have Voted to Re-Elect Steven A. Kriegsman and Dr. Louis Ignarro to the Board Releases New Presentation Summarizing the Company’s Strategic Priorities and Path to Delivering Long-Term Value for Stockholders CytRx Corporation (OTCQB: CYTR) (...
News, Short Squeeze, Breakout and More Instantly...
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, Octo...
The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceut...
Patent Protects the LADR Platform and Drugs Employing LADR CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has...